| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Penile Neoplasms | 62 | 2024 | 161 | 18.410 |
Why?
|
| Prostatic Neoplasms | 124 | 2024 | 5767 | 5.320 |
Why?
|
| Lymph Node Excision | 32 | 2024 | 1959 | 3.170 |
Why?
|
| Prostatectomy | 44 | 2024 | 962 | 3.020 |
Why?
|
| Carcinoma, Squamous Cell | 34 | 2023 | 5437 | 2.830 |
Why?
|
| Prostate-Specific Antigen | 34 | 2020 | 993 | 1.710 |
Why?
|
| Inguinal Canal | 9 | 2024 | 60 | 1.350 |
Why?
|
| Papillomavirus Infections | 8 | 2023 | 980 | 1.320 |
Why?
|
| Male | 210 | 2024 | 123000 | 1.310 |
Why?
|
| Germ-Line Mutation | 4 | 2021 | 1046 | 1.290 |
Why?
|
| Robotics | 4 | 2018 | 359 | 1.240 |
Why?
|
| Penis | 7 | 2023 | 123 | 1.200 |
Why?
|
| Genital Neoplasms, Male | 5 | 2017 | 44 | 1.190 |
Why?
|
| Paget Disease, Extramammary | 3 | 2022 | 55 | 1.170 |
Why?
|
| Robotic Surgical Procedures | 6 | 2024 | 481 | 1.150 |
Why?
|
| Lymphatic Metastasis | 32 | 2023 | 4844 | 1.050 |
Why?
|
| Genetic Predisposition to Disease | 16 | 2021 | 5539 | 1.040 |
Why?
|
| Androgen Antagonists | 10 | 2017 | 411 | 1.040 |
Why?
|
| Prostate | 12 | 2024 | 1088 | 0.990 |
Why?
|
| Urethral Neoplasms | 6 | 2017 | 60 | 0.980 |
Why?
|
| Humans | 223 | 2024 | 261506 | 0.880 |
Why?
|
| Neoplasm Staging | 41 | 2024 | 13658 | 0.840 |
Why?
|
| Lymph Nodes | 9 | 2024 | 2967 | 0.820 |
Why?
|
| Adenocarcinoma | 18 | 2017 | 7789 | 0.780 |
Why?
|
| Matrix Metalloproteinase 9 | 6 | 2008 | 360 | 0.740 |
Why?
|
| Sentinel Lymph Node Biopsy | 6 | 2023 | 1415 | 0.710 |
Why?
|
| Matrix Metalloproteinase 2 | 3 | 2008 | 256 | 0.690 |
Why?
|
| Antineoplastic Agents, Hormonal | 6 | 2017 | 840 | 0.680 |
Why?
|
| Organ Sparing Treatments | 1 | 2021 | 277 | 0.670 |
Why?
|
| Resource Allocation | 1 | 2019 | 67 | 0.670 |
Why?
|
| Combined Modality Therapy | 25 | 2022 | 8865 | 0.660 |
Why?
|
| Watchful Waiting | 5 | 2020 | 289 | 0.660 |
Why?
|
| Middle Aged | 114 | 2023 | 86204 | 0.650 |
Why?
|
| Genetic Testing | 4 | 2021 | 1589 | 0.640 |
Why?
|
| Aged | 101 | 2023 | 70117 | 0.630 |
Why?
|
| Cadherins | 5 | 2008 | 660 | 0.610 |
Why?
|
| Insurance, Health | 1 | 2019 | 250 | 0.580 |
Why?
|
| Quality of Life | 12 | 2023 | 4532 | 0.580 |
Why?
|
| Scrotum | 3 | 2014 | 57 | 0.580 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p16 | 2 | 2019 | 476 | 0.570 |
Why?
|
| Prostatic Hyperplasia | 3 | 2011 | 210 | 0.540 |
Why?
|
| Neoplasm Grading | 12 | 2021 | 1742 | 0.530 |
Why?
|
| Neoplasm Recurrence, Local | 21 | 2023 | 10035 | 0.520 |
Why?
|
| Spouses | 2 | 2021 | 134 | 0.520 |
Why?
|
| Taxoids | 4 | 2017 | 967 | 0.510 |
Why?
|
| Biomarkers, Tumor | 14 | 2021 | 10331 | 0.510 |
Why?
|
| Urology | 3 | 2023 | 128 | 0.460 |
Why?
|
| Carcinoma in Situ | 2 | 2017 | 487 | 0.450 |
Why?
|
| Video-Assisted Surgery | 1 | 2013 | 28 | 0.450 |
Why?
|
| Prognosis | 28 | 2022 | 21713 | 0.450 |
Why?
|
| Polymorphism, Single Nucleotide | 13 | 2021 | 4549 | 0.450 |
Why?
|
| Life Style | 7 | 2021 | 612 | 0.440 |
Why?
|
| Neoplasm Invasiveness | 12 | 2007 | 3981 | 0.430 |
Why?
|
| Neoplasms, Squamous Cell | 1 | 2012 | 87 | 0.430 |
Why?
|
| Neoadjuvant Therapy | 12 | 2017 | 4975 | 0.420 |
Why?
|
| Carcinoma | 3 | 2022 | 2578 | 0.410 |
Why?
|
| Postoperative Period | 3 | 2011 | 665 | 0.400 |
Why?
|
| Delivery of Health Care | 1 | 2019 | 860 | 0.400 |
Why?
|
| Urinary Retention | 1 | 2011 | 21 | 0.390 |
Why?
|
| Gene Expression Regulation, Neoplastic | 10 | 2021 | 8873 | 0.390 |
Why?
|
| Neoplasm Metastasis | 13 | 2021 | 5112 | 0.380 |
Why?
|
| Biopsy | 12 | 2019 | 3443 | 0.380 |
Why?
|
| Treatment Outcome | 37 | 2023 | 32848 | 0.360 |
Why?
|
| RNA, Messenger | 9 | 2009 | 6150 | 0.360 |
Why?
|
| Prospective Studies | 20 | 2022 | 12873 | 0.350 |
Why?
|
| Proto-Oncogene Proteins c-bcl-2 | 3 | 2010 | 1493 | 0.350 |
Why?
|
| Pelvic Neoplasms | 1 | 2010 | 189 | 0.330 |
Why?
|
| Leuprolide | 1 | 2008 | 65 | 0.330 |
Why?
|
| Receptors, Platelet-Derived Growth Factor | 1 | 2008 | 104 | 0.330 |
Why?
|
| Genome-Wide Association Study | 8 | 2021 | 2265 | 0.320 |
Why?
|
| Interleukin-8 | 6 | 2016 | 519 | 0.320 |
Why?
|
| Risk Factors | 23 | 2021 | 17523 | 0.320 |
Why?
|
| Receptors, Androgen | 4 | 2016 | 878 | 0.310 |
Why?
|
| 5-alpha Reductase Inhibitors | 4 | 2011 | 20 | 0.310 |
Why?
|
| Cystectomy | 8 | 2021 | 623 | 0.310 |
Why?
|
| Aged, 80 and over | 28 | 2021 | 29902 | 0.310 |
Why?
|
| Adult | 49 | 2021 | 77950 | 0.310 |
Why?
|
| Laparoscopy | 3 | 2016 | 1225 | 0.300 |
Why?
|
| Androgens | 7 | 2011 | 511 | 0.300 |
Why?
|
| Carcinoma, Transitional Cell | 7 | 2012 | 962 | 0.300 |
Why?
|
| Azasteroids | 3 | 2011 | 11 | 0.290 |
Why?
|
| Apoptosis | 9 | 2016 | 7591 | 0.290 |
Why?
|
| Urinary Bladder Neoplasms | 9 | 2021 | 2341 | 0.290 |
Why?
|
| Antineoplastic Agents | 11 | 2023 | 14289 | 0.280 |
Why?
|
| Sexual Dysfunction, Physiological | 1 | 2007 | 129 | 0.280 |
Why?
|
| Body Height | 2 | 2021 | 231 | 0.270 |
Why?
|
| Retrospective Studies | 30 | 2024 | 37905 | 0.270 |
Why?
|
| Disease Management | 3 | 2021 | 1052 | 0.260 |
Why?
|
| Hemoglobins | 1 | 2007 | 477 | 0.260 |
Why?
|
| Down-Regulation | 1 | 2010 | 2074 | 0.250 |
Why?
|
| Cancer Survivors | 2 | 2021 | 650 | 0.250 |
Why?
|
| Plasminogen Activators | 1 | 2004 | 52 | 0.250 |
Why?
|
| Obesity | 7 | 2024 | 2884 | 0.240 |
Why?
|
| Endothelial Growth Factors | 4 | 2001 | 197 | 0.240 |
Why?
|
| Hemangioendothelioma | 1 | 2004 | 35 | 0.240 |
Why?
|
| Chemotherapy, Adjuvant | 6 | 2015 | 3890 | 0.240 |
Why?
|
| Urokinase-Type Plasminogen Activator | 1 | 2004 | 136 | 0.240 |
Why?
|
| Lymphokines | 4 | 2001 | 272 | 0.240 |
Why?
|
| Hepatocyte Growth Factor | 1 | 2004 | 142 | 0.230 |
Why?
|
| Predictive Value of Tests | 10 | 2017 | 4892 | 0.230 |
Why?
|
| Stress, Psychological | 4 | 2012 | 1000 | 0.230 |
Why?
|
| Neovascularization, Pathologic | 8 | 2016 | 1547 | 0.230 |
Why?
|
| Urogenital Neoplasms | 2 | 2021 | 108 | 0.230 |
Why?
|
| Uterine Cervical Neoplasms | 3 | 2023 | 1833 | 0.220 |
Why?
|
| United States | 17 | 2019 | 15433 | 0.220 |
Why?
|
| Antineoplastic Agents, Immunological | 2 | 2023 | 1249 | 0.220 |
Why?
|
| Neoplasms, Hormone-Dependent | 2 | 2017 | 342 | 0.220 |
Why?
|
| Randomized Controlled Trials as Topic | 4 | 2019 | 2594 | 0.220 |
Why?
|
| Interferon-alpha | 2 | 2004 | 889 | 0.220 |
Why?
|
| Testosterone | 1 | 2007 | 619 | 0.210 |
Why?
|
| Risk Assessment | 9 | 2021 | 6869 | 0.210 |
Why?
|
| Early Detection of Cancer | 4 | 2021 | 1258 | 0.210 |
Why?
|
| Patient Selection | 7 | 2019 | 2055 | 0.200 |
Why?
|
| Ecological Momentary Assessment | 1 | 2021 | 21 | 0.200 |
Why?
|
| Follow-Up Studies | 18 | 2020 | 14889 | 0.200 |
Why?
|
| Disease-Free Survival | 15 | 2017 | 10001 | 0.200 |
Why?
|
| Collagenases | 2 | 2000 | 74 | 0.200 |
Why?
|
| Checkpoint Kinase 2 | 1 | 2021 | 126 | 0.200 |
Why?
|
| Urologic Surgical Procedures, Male | 1 | 2021 | 43 | 0.190 |
Why?
|
| Cyclobutanes | 1 | 2021 | 36 | 0.190 |
Why?
|
| Incidence | 7 | 2021 | 5673 | 0.190 |
Why?
|
| Survival Rate | 12 | 2017 | 12221 | 0.190 |
Why?
|
| Carboxylic Acids | 1 | 2021 | 57 | 0.190 |
Why?
|
| Health Knowledge, Attitudes, Practice | 2 | 2014 | 1209 | 0.190 |
Why?
|
| Disease Progression | 14 | 2019 | 6682 | 0.190 |
Why?
|
| Salvage Therapy | 7 | 2016 | 2054 | 0.190 |
Why?
|
| Telomere Homeostasis | 1 | 2020 | 73 | 0.180 |
Why?
|
| Health Behavior | 2 | 2021 | 603 | 0.180 |
Why?
|
| Case-Control Studies | 7 | 2021 | 6100 | 0.180 |
Why?
|
| Epigenomics | 1 | 2021 | 266 | 0.180 |
Why?
|
| Genetic Loci | 4 | 2016 | 481 | 0.180 |
Why?
|
| Postoperative Complications | 7 | 2020 | 5542 | 0.180 |
Why?
|
| Papillomavirus Vaccines | 1 | 2022 | 195 | 0.180 |
Why?
|
| Feasibility Studies | 9 | 2021 | 2292 | 0.180 |
Why?
|
| Piperazines | 1 | 2008 | 2101 | 0.180 |
Why?
|
| DNA Mismatch Repair | 1 | 2021 | 268 | 0.170 |
Why?
|
| In Situ Hybridization | 6 | 2005 | 1037 | 0.170 |
Why?
|
| Incidental Findings | 1 | 2021 | 272 | 0.170 |
Why?
|
| Ataxia Telangiectasia Mutated Proteins | 1 | 2021 | 430 | 0.170 |
Why?
|
| Surgical Wound Infection | 2 | 2016 | 450 | 0.170 |
Why?
|
| Health Care Costs | 2 | 2019 | 674 | 0.170 |
Why?
|
| Cystostomy | 2 | 2010 | 13 | 0.170 |
Why?
|
| Tertiary Care Centers | 1 | 2021 | 403 | 0.170 |
Why?
|
| Adaptation, Psychological | 6 | 2021 | 764 | 0.170 |
Why?
|
| Antineoplastic Agents, Phytogenic | 2 | 2015 | 852 | 0.170 |
Why?
|
| Urologic Neoplasms | 1 | 2021 | 188 | 0.170 |
Why?
|
| Urinary Bladder | 1 | 2021 | 575 | 0.170 |
Why?
|
| Signal Transduction | 5 | 2012 | 11965 | 0.160 |
Why?
|
| Leukocytes | 1 | 2020 | 422 | 0.160 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 5 | 2023 | 15862 | 0.160 |
Why?
|
| Decision Making | 3 | 2016 | 1287 | 0.160 |
Why?
|
| BRCA1 Protein | 1 | 2021 | 493 | 0.160 |
Why?
|
| Disease Susceptibility | 1 | 2021 | 538 | 0.160 |
Why?
|
| Time Factors | 12 | 2018 | 12926 | 0.160 |
Why?
|
| Education, Medical, Graduate | 2 | 2017 | 671 | 0.160 |
Why?
|
| Immunohistochemistry | 11 | 2020 | 7548 | 0.160 |
Why?
|
| Cohort Studies | 11 | 2017 | 9244 | 0.150 |
Why?
|
| Urinary Incontinence | 2 | 2010 | 149 | 0.150 |
Why?
|
| Selenomethionine | 2 | 2009 | 41 | 0.150 |
Why?
|
| Groin | 2 | 2009 | 74 | 0.150 |
Why?
|
| Neoplasms, Germ Cell and Embryonal | 1 | 2020 | 328 | 0.150 |
Why?
|
| Analysis of Variance | 5 | 2017 | 2307 | 0.150 |
Why?
|
| Testicular Neoplasms | 3 | 2008 | 529 | 0.150 |
Why?
|
| Logistic Models | 8 | 2017 | 3441 | 0.150 |
Why?
|
| Thapsigargin | 1 | 1996 | 38 | 0.150 |
Why?
|
| Colorectal Neoplasms, Hereditary Nonpolyposis | 1 | 2021 | 469 | 0.150 |
Why?
|
| Urethra | 1 | 2017 | 144 | 0.150 |
Why?
|
| Rare Diseases | 2 | 2023 | 351 | 0.150 |
Why?
|
| Bulbourethral Glands | 1 | 2016 | 8 | 0.150 |
Why?
|
| Doxorubicin | 3 | 2001 | 3005 | 0.150 |
Why?
|
| Kaplan-Meier Estimate | 5 | 2015 | 6207 | 0.140 |
Why?
|
| Tumor Cells, Cultured | 12 | 2004 | 5395 | 0.140 |
Why?
|
| SEER Program | 5 | 2019 | 1000 | 0.140 |
Why?
|
| Neoplasm Proteins | 3 | 2011 | 3230 | 0.140 |
Why?
|
| B7 Antigens | 1 | 2017 | 84 | 0.140 |
Why?
|
| Exercise | 4 | 2021 | 1183 | 0.140 |
Why?
|
| Chemokine CXCL1 | 1 | 2016 | 60 | 0.140 |
Why?
|
| Tissue Array Analysis | 4 | 2020 | 760 | 0.140 |
Why?
|
| Cell Division | 7 | 2004 | 2489 | 0.140 |
Why?
|
| Finasteride | 1 | 2016 | 31 | 0.140 |
Why?
|
| Caveolin 1 | 1 | 2017 | 204 | 0.140 |
Why?
|
| Neoplasms, Multiple Primary | 2 | 2016 | 551 | 0.140 |
Why?
|
| Cell Transdifferentiation | 1 | 2017 | 112 | 0.140 |
Why?
|
| Pyrimidines | 1 | 2008 | 3518 | 0.140 |
Why?
|
| Mice, Nude | 13 | 2016 | 4307 | 0.140 |
Why?
|
| Orchiectomy | 2 | 2012 | 214 | 0.140 |
Why?
|
| Lythraceae | 1 | 2015 | 2 | 0.140 |
Why?
|
| Inheritance Patterns | 1 | 2016 | 139 | 0.130 |
Why?
|
| Preoperative Care | 5 | 2011 | 1529 | 0.130 |
Why?
|
| Carcinogens | 1 | 1996 | 384 | 0.130 |
Why?
|
| Pilot Projects | 3 | 2021 | 2803 | 0.130 |
Why?
|
| Intestine, Large | 1 | 2015 | 28 | 0.130 |
Why?
|
| Positron Emission Tomography Computed Tomography | 1 | 2021 | 833 | 0.130 |
Why?
|
| Palliative Care | 3 | 2018 | 2037 | 0.130 |
Why?
|
| Ureteral Neoplasms | 2 | 2007 | 228 | 0.130 |
Why?
|
| Radionuclide Imaging | 2 | 2007 | 660 | 0.130 |
Why?
|
| Chromosomes, Human, Pair 8 | 1 | 2016 | 317 | 0.120 |
Why?
|
| Brachytherapy | 2 | 2019 | 977 | 0.120 |
Why?
|
| Texas | 5 | 2021 | 6311 | 0.120 |
Why?
|
| Computational Biology | 1 | 2021 | 1271 | 0.120 |
Why?
|
| Body Mass Index | 4 | 2024 | 2203 | 0.120 |
Why?
|
| Patient Satisfaction | 4 | 2017 | 915 | 0.120 |
Why?
|
| Tumor Microenvironment | 3 | 2023 | 2864 | 0.120 |
Why?
|
| Diet | 1 | 2021 | 1440 | 0.120 |
Why?
|
| Body Fat Distribution | 1 | 2013 | 29 | 0.120 |
Why?
|
| Erectile Dysfunction | 3 | 2013 | 212 | 0.110 |
Why?
|
| Plant Extracts | 1 | 2015 | 215 | 0.110 |
Why?
|
| Prostatic Neoplasms, Castration-Resistant | 1 | 2018 | 425 | 0.110 |
Why?
|
| Epigenesis, Genetic | 2 | 2021 | 1399 | 0.110 |
Why?
|
| Poly(ADP-ribose) Polymerases | 2 | 2010 | 324 | 0.110 |
Why?
|
| Antibiotics, Antineoplastic | 1 | 1996 | 726 | 0.110 |
Why?
|
| Socioeconomic Factors | 4 | 2012 | 1225 | 0.110 |
Why?
|
| Genetic Linkage | 2 | 2007 | 512 | 0.110 |
Why?
|
| Antibodies | 2 | 2009 | 838 | 0.110 |
Why?
|
| Female | 23 | 2023 | 141928 | 0.110 |
Why?
|
| Oropharyngeal Neoplasms | 1 | 2021 | 1105 | 0.110 |
Why?
|
| Surveys and Questionnaires | 8 | 2021 | 5687 | 0.110 |
Why?
|
| Ureterostomy | 1 | 2012 | 8 | 0.110 |
Why?
|
| Carcinoma, Adenoid Cystic | 1 | 2016 | 421 | 0.110 |
Why?
|
| Practice Patterns, Physicians' | 1 | 2021 | 1303 | 0.110 |
Why?
|
| Medical Oncology | 1 | 2021 | 1423 | 0.110 |
Why?
|
| Ureter | 2 | 2012 | 209 | 0.110 |
Why?
|
| Cisplatin | 4 | 2020 | 2432 | 0.100 |
Why?
|
| Neuroendocrine Tumors | 2 | 2017 | 634 | 0.100 |
Why?
|
| Hedgehog Proteins | 2 | 2012 | 424 | 0.100 |
Why?
|
| Antibodies, Monoclonal | 3 | 2023 | 4367 | 0.100 |
Why?
|
| Urinary Catheterization | 2 | 2010 | 117 | 0.100 |
Why?
|
| Fibroblast Growth Factor 2 | 4 | 2007 | 223 | 0.100 |
Why?
|
| Managed Care Programs | 1 | 2011 | 74 | 0.100 |
Why?
|
| Macrophages | 2 | 2017 | 1304 | 0.100 |
Why?
|
| DNA Methylation | 1 | 2021 | 2669 | 0.100 |
Why?
|
| Michigan | 1 | 2011 | 67 | 0.100 |
Why?
|
| Radiotherapy, Adjuvant | 3 | 2016 | 2231 | 0.100 |
Why?
|
| Blood Loss, Surgical | 2 | 2016 | 309 | 0.100 |
Why?
|
| Organ Size | 2 | 2006 | 690 | 0.100 |
Why?
|
| Adrenergic alpha-Antagonists | 1 | 2011 | 67 | 0.100 |
Why?
|
| ErbB Receptors | 2 | 2014 | 2295 | 0.100 |
Why?
|
| Antibodies, Monoclonal, Humanized | 2 | 2021 | 3251 | 0.090 |
Why?
|
| Carcinoma, Small Cell | 2 | 2007 | 408 | 0.090 |
Why?
|
| Human papillomavirus 16 | 2 | 2023 | 256 | 0.090 |
Why?
|
| Sexuality | 1 | 2010 | 38 | 0.090 |
Why?
|
| Cell Line, Tumor | 8 | 2017 | 14551 | 0.090 |
Why?
|
| Molecular Targeted Therapy | 1 | 2021 | 2330 | 0.090 |
Why?
|
| Cytochromes c | 1 | 2010 | 118 | 0.090 |
Why?
|
| B7-H1 Antigen | 1 | 2017 | 1022 | 0.090 |
Why?
|
| Patient Participation | 1 | 2014 | 446 | 0.090 |
Why?
|
| Teaching | 2 | 2009 | 243 | 0.090 |
Why?
|
| Antibody Formation | 1 | 2011 | 383 | 0.090 |
Why?
|
| Proportional Hazards Models | 7 | 2017 | 4988 | 0.090 |
Why?
|
| Mice, Inbred BALB C | 8 | 2005 | 2314 | 0.090 |
Why?
|
| Creatinine | 1 | 2012 | 531 | 0.090 |
Why?
|
| Ifosfamide | 1 | 2010 | 344 | 0.090 |
Why?
|
| Ileostomy | 1 | 2010 | 46 | 0.090 |
Why?
|
| Linkage Disequilibrium | 3 | 2016 | 460 | 0.090 |
Why?
|
| Health Status Indicators | 1 | 2010 | 224 | 0.080 |
Why?
|
| Xenograft Model Antitumor Assays | 5 | 2016 | 3821 | 0.080 |
Why?
|
| Skin Neoplasms | 3 | 2022 | 4654 | 0.080 |
Why?
|
| alpha-Tocopherol | 1 | 2009 | 78 | 0.080 |
Why?
|
| Lymphocele | 1 | 2008 | 8 | 0.080 |
Why?
|
| Pathology, Clinical | 1 | 2010 | 152 | 0.080 |
Why?
|
| Trauma, Nervous System | 1 | 2008 | 10 | 0.080 |
Why?
|
| Genetic Markers | 2 | 2009 | 974 | 0.080 |
Why?
|
| Treatment Failure | 4 | 2015 | 1391 | 0.080 |
Why?
|
| Educational Status | 1 | 2010 | 397 | 0.080 |
Why?
|
| Sural Nerve | 1 | 2008 | 54 | 0.080 |
Why?
|
| Chromosome Mapping | 3 | 2015 | 1471 | 0.080 |
Why?
|
| Polymorphism, Genetic | 3 | 2005 | 1450 | 0.080 |
Why?
|
| Clinical Trials as Topic | 2 | 2014 | 3719 | 0.080 |
Why?
|
| RNA, Small Interfering | 2 | 2016 | 2216 | 0.080 |
Why?
|
| Mice | 17 | 2020 | 34495 | 0.080 |
Why?
|
| Decision Support Techniques | 1 | 2014 | 622 | 0.080 |
Why?
|
| Affect | 1 | 2010 | 288 | 0.080 |
Why?
|
| Vascular Endothelial Growth Factor A | 7 | 2007 | 1533 | 0.080 |
Why?
|
| Military Personnel | 1 | 2011 | 225 | 0.080 |
Why?
|
| Double-Blind Method | 5 | 2016 | 2588 | 0.080 |
Why?
|
| Cell Movement | 1 | 2016 | 2466 | 0.080 |
Why?
|
| Glomerular Filtration Rate | 1 | 2012 | 602 | 0.080 |
Why?
|
| Penile Erection | 1 | 2008 | 86 | 0.080 |
Why?
|
| Linear Models | 4 | 2009 | 1085 | 0.080 |
Why?
|
| Social Support | 2 | 2012 | 560 | 0.080 |
Why?
|
| Endoribonucleases | 1 | 2008 | 107 | 0.080 |
Why?
|
| Vascular Endothelial Growth Factors | 4 | 2001 | 212 | 0.080 |
Why?
|
| Cryoglobulins | 1 | 1987 | 14 | 0.080 |
Why?
|
| Gonadotropin-Releasing Hormone | 1 | 2008 | 167 | 0.080 |
Why?
|
| Surgical Wound Dehiscence | 1 | 2008 | 129 | 0.080 |
Why?
|
| Clinical Protocols | 1 | 2010 | 467 | 0.080 |
Why?
|
| Models, Economic | 1 | 2008 | 101 | 0.080 |
Why?
|
| Neoplasm Transplantation | 6 | 2003 | 1519 | 0.080 |
Why?
|
| Antigen-Presenting Cells | 1 | 1988 | 284 | 0.080 |
Why?
|
| Caspases | 1 | 2010 | 661 | 0.080 |
Why?
|
| Technetium Tc 99m Sulfur Colloid | 1 | 2007 | 115 | 0.080 |
Why?
|
| Pelvis | 2 | 2021 | 362 | 0.070 |
Why?
|
| Rosaniline Dyes | 1 | 2007 | 108 | 0.070 |
Why?
|
| Dutasteride | 3 | 2011 | 10 | 0.070 |
Why?
|
| Kidney Pelvis | 1 | 2007 | 102 | 0.070 |
Why?
|
| Genes, p53 | 2 | 2004 | 1090 | 0.070 |
Why?
|
| Chylous Ascites | 1 | 2006 | 25 | 0.070 |
Why?
|
| Anticarcinogenic Agents | 1 | 2009 | 362 | 0.070 |
Why?
|
| Psychotherapy, Group | 1 | 2007 | 59 | 0.070 |
Why?
|
| Coloring Agents | 1 | 2007 | 234 | 0.070 |
Why?
|
| Pelvic Exenteration | 2 | 2005 | 108 | 0.070 |
Why?
|
| Magnetic Resonance Imaging | 5 | 2021 | 7702 | 0.070 |
Why?
|
| Immunotherapy | 1 | 2020 | 3341 | 0.070 |
Why?
|
| Mental Health | 1 | 2010 | 415 | 0.070 |
Why?
|
| Dietary Fats | 1 | 2008 | 339 | 0.070 |
Why?
|
| Internship and Residency | 1 | 2017 | 1375 | 0.070 |
Why?
|
| Genotype | 5 | 2015 | 4109 | 0.070 |
Why?
|
| Neuropilins | 1 | 2006 | 14 | 0.070 |
Why?
|
| Drug Therapy, Combination | 2 | 2009 | 2315 | 0.070 |
Why?
|
| Endosonography | 2 | 2011 | 536 | 0.070 |
Why?
|
| Weight Gain | 2 | 2008 | 464 | 0.070 |
Why?
|
| Multivariate Analysis | 4 | 2017 | 4298 | 0.070 |
Why?
|
| Receptor, EphB2 | 1 | 2005 | 17 | 0.070 |
Why?
|
| Mexican Americans | 1 | 2008 | 322 | 0.070 |
Why?
|
| Teratoma | 1 | 2008 | 236 | 0.070 |
Why?
|
| Cell Proliferation | 4 | 2016 | 7226 | 0.070 |
Why?
|
| Medically Underserved Area | 1 | 2006 | 101 | 0.070 |
Why?
|
| Psychometrics | 1 | 2010 | 937 | 0.070 |
Why?
|
| Endothelium, Vascular | 3 | 2006 | 891 | 0.070 |
Why?
|
| Animals | 18 | 2020 | 59536 | 0.070 |
Why?
|
| Lymphedema | 1 | 2008 | 239 | 0.070 |
Why?
|
| Paclitaxel | 2 | 2010 | 1996 | 0.060 |
Why?
|
| Kidney Transplantation | 2 | 1989 | 755 | 0.060 |
Why?
|
| Vitamin E | 1 | 2005 | 136 | 0.060 |
Why?
|
| Codon, Nonsense | 1 | 2005 | 164 | 0.060 |
Why?
|
| Pulmonary Embolism | 1 | 2008 | 329 | 0.060 |
Why?
|
| Venous Thrombosis | 1 | 2008 | 384 | 0.060 |
Why?
|
| Pedigree | 4 | 2017 | 1890 | 0.060 |
Why?
|
| Urban Population | 1 | 2006 | 269 | 0.060 |
Why?
|
| Cross-Sectional Studies | 2 | 2021 | 4314 | 0.060 |
Why?
|
| Length of Stay | 2 | 2009 | 1900 | 0.060 |
Why?
|
| Interferon-gamma | 1 | 2009 | 1144 | 0.060 |
Why?
|
| Flow Cytometry | 3 | 2017 | 3033 | 0.060 |
Why?
|
| Blood Transfusion | 1 | 2008 | 583 | 0.060 |
Why?
|
| Imatinib Mesylate | 1 | 2008 | 1665 | 0.060 |
Why?
|
| Drug Administration Schedule | 1 | 2010 | 3472 | 0.060 |
Why?
|
| Biopsy, Needle | 2 | 2006 | 1363 | 0.060 |
Why?
|
| Kinetics | 1 | 2007 | 2049 | 0.060 |
Why?
|
| Longitudinal Studies | 2 | 2021 | 1945 | 0.060 |
Why?
|
| Gene Frequency | 3 | 2013 | 1163 | 0.060 |
Why?
|
| Receptors, Transforming Growth Factor beta | 1 | 2005 | 229 | 0.060 |
Why?
|
| Autoantibodies | 1 | 1987 | 576 | 0.060 |
Why?
|
| Antigens, CD | 1 | 2009 | 1385 | 0.060 |
Why?
|
| Lymphocytes, Tumor-Infiltrating | 1 | 2009 | 992 | 0.060 |
Why?
|
| Radiotherapy Planning, Computer-Assisted | 1 | 2014 | 2370 | 0.060 |
Why?
|
| CD4-Positive T-Lymphocytes | 1 | 2009 | 1033 | 0.060 |
Why?
|
| Simplexvirus | 1 | 2004 | 159 | 0.060 |
Why?
|
| Human papillomavirus 18 | 1 | 2023 | 43 | 0.060 |
Why?
|
| Thalidomide | 1 | 2007 | 569 | 0.060 |
Why?
|
| Monitoring, Intraoperative | 1 | 2005 | 264 | 0.060 |
Why?
|
| Seminal Vesicles | 2 | 2005 | 152 | 0.060 |
Why?
|
| Perineum | 1 | 2003 | 107 | 0.060 |
Why?
|
| Kidney Neoplasms | 2 | 2007 | 3022 | 0.060 |
Why?
|
| Benzamides | 1 | 2008 | 1832 | 0.060 |
Why?
|
| Sensitivity and Specificity | 3 | 2007 | 4971 | 0.060 |
Why?
|
| Prevalence | 1 | 2011 | 3260 | 0.060 |
Why?
|
| Neoplastic Stem Cells | 1 | 2011 | 1443 | 0.060 |
Why?
|
| Puerto Rico | 2 | 2012 | 65 | 0.060 |
Why?
|
| Up-Regulation | 3 | 2004 | 2450 | 0.060 |
Why?
|
| Kidney | 1 | 2012 | 2146 | 0.050 |
Why?
|
| Vaccination Coverage | 1 | 2022 | 37 | 0.050 |
Why?
|
| Multienzyme Complexes | 1 | 2003 | 213 | 0.050 |
Why?
|
| Ultrasonography | 2 | 2018 | 1863 | 0.050 |
Why?
|
| Enzyme Inhibitors | 1 | 2010 | 1879 | 0.050 |
Why?
|
| Algorithms | 2 | 2010 | 3890 | 0.050 |
Why?
|
| Protease Inhibitors | 1 | 2003 | 210 | 0.050 |
Why?
|
| Antioxidants | 1 | 2005 | 507 | 0.050 |
Why?
|
| Mutation | 2 | 2021 | 15179 | 0.050 |
Why?
|
| Pain, Intractable | 1 | 2003 | 171 | 0.050 |
Why?
|
| Endothelium | 1 | 2002 | 158 | 0.050 |
Why?
|
| Nephrectomy | 1 | 2006 | 779 | 0.050 |
Why?
|
| Goals | 1 | 2023 | 185 | 0.050 |
Why?
|
| Risk | 2 | 2020 | 1972 | 0.050 |
Why?
|
| Aggression | 1 | 2024 | 252 | 0.050 |
Why?
|
| Retroperitoneal Space | 3 | 2008 | 145 | 0.050 |
Why?
|
| Radiopharmaceuticals | 1 | 2007 | 1301 | 0.050 |
Why?
|
| Minimally Invasive Surgical Procedures | 2 | 2017 | 500 | 0.050 |
Why?
|
| Boronic Acids | 1 | 2003 | 362 | 0.050 |
Why?
|
| Mouthwashes | 1 | 2021 | 41 | 0.050 |
Why?
|
| Cost-Benefit Analysis | 2 | 2018 | 945 | 0.050 |
Why?
|
| Activities of Daily Living | 1 | 2004 | 552 | 0.050 |
Why?
|
| Patient Acuity | 1 | 2021 | 72 | 0.050 |
Why?
|
| Vascular Endothelial Growth Factor Receptor-2 | 1 | 2002 | 272 | 0.050 |
Why?
|
| Africa | 1 | 2021 | 142 | 0.050 |
Why?
|
| I-kappa B Proteins | 1 | 2001 | 170 | 0.050 |
Why?
|
| Neoplasms | 3 | 2014 | 15193 | 0.050 |
Why?
|
| Patient Education as Topic | 3 | 2014 | 748 | 0.050 |
Why?
|
| Pyrazines | 1 | 2003 | 495 | 0.050 |
Why?
|
| Oligonucleotide Probes | 1 | 2000 | 130 | 0.050 |
Why?
|
| Estramustine | 1 | 2000 | 26 | 0.050 |
Why?
|
| Promoter Regions, Genetic | 3 | 2021 | 3101 | 0.050 |
Why?
|
| Ketoconazole | 1 | 2000 | 34 | 0.050 |
Why?
|
| Antigens, Surface | 1 | 2001 | 295 | 0.050 |
Why?
|
| T-Lymphocytes | 2 | 2017 | 3869 | 0.050 |
Why?
|
| Societies, Medical | 2 | 2021 | 1335 | 0.050 |
Why?
|
| 3-Oxo-5-alpha-Steroid 4-Dehydrogenase | 1 | 1999 | 18 | 0.050 |
Why?
|
| Overweight | 1 | 2024 | 484 | 0.050 |
Why?
|
| Leukocytes, Mononuclear | 1 | 2023 | 709 | 0.040 |
Why?
|
| Chromosomes, Human, Pair 1 | 1 | 2001 | 327 | 0.040 |
Why?
|
| SOXB1 Transcription Factors | 1 | 2020 | 123 | 0.040 |
Why?
|
| Health Care Surveys | 1 | 2021 | 430 | 0.040 |
Why?
|
| Transcriptional Regulator ERG | 1 | 2019 | 61 | 0.040 |
Why?
|
| CpG Islands | 1 | 2021 | 633 | 0.040 |
Why?
|
| Myeloid-Derived Suppressor Cells | 1 | 2020 | 100 | 0.040 |
Why?
|
| Europe | 1 | 2021 | 649 | 0.040 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 2 | 2017 | 1489 | 0.040 |
Why?
|
| Vinblastine | 1 | 2000 | 453 | 0.040 |
Why?
|
| Cryotherapy | 1 | 1999 | 67 | 0.040 |
Why?
|
| Interferon-beta | 1 | 1999 | 102 | 0.040 |
Why?
|
| Chromosome Disorders | 1 | 2001 | 417 | 0.040 |
Why?
|
| Genetic Therapy | 2 | 2004 | 1616 | 0.040 |
Why?
|
| Cancer Vaccines | 1 | 2004 | 697 | 0.040 |
Why?
|
| Myeloid Cells | 1 | 2020 | 269 | 0.040 |
Why?
|
| Health Status | 1 | 2021 | 590 | 0.040 |
Why?
|
| Age Factors | 3 | 2017 | 5377 | 0.040 |
Why?
|
| Minority Groups | 1 | 2020 | 322 | 0.040 |
Why?
|
| Heredity | 1 | 2017 | 29 | 0.040 |
Why?
|
| Phenotype | 3 | 2017 | 6295 | 0.040 |
Why?
|
| History, 20th Century | 1 | 2020 | 574 | 0.040 |
Why?
|
| Transfection | 4 | 2005 | 2944 | 0.040 |
Why?
|
| Mass Screening | 1 | 2006 | 1509 | 0.040 |
Why?
|
| Diagnostic Imaging | 1 | 2005 | 1162 | 0.040 |
Why?
|
| Alaska Natives | 1 | 2017 | 3 | 0.040 |
Why?
|
| Mice, Inbred C57BL | 2 | 2020 | 6942 | 0.040 |
Why?
|
| Proteomics | 2 | 2020 | 1380 | 0.040 |
Why?
|
| American Cancer Society | 1 | 2016 | 31 | 0.040 |
Why?
|
| Recurrence | 2 | 2021 | 4758 | 0.040 |
Why?
|
| Cell Line | 2 | 2020 | 5114 | 0.040 |
Why?
|
| Indians, North American | 1 | 2017 | 87 | 0.040 |
Why?
|
| Receptors, Interleukin-8A | 1 | 2016 | 16 | 0.040 |
Why?
|
| Fluorescent Antibody Technique | 2 | 2017 | 1062 | 0.040 |
Why?
|
| Immunosuppressive Agents | 1 | 2023 | 1375 | 0.040 |
Why?
|
| Rectal Neoplasms | 1 | 2005 | 1202 | 0.040 |
Why?
|
| Dihydrotestosterone | 1 | 1996 | 118 | 0.040 |
Why?
|
| Blotting, Northern | 3 | 2005 | 682 | 0.040 |
Why?
|
| Drug Resistance, Neoplasm | 3 | 2008 | 5178 | 0.030 |
Why?
|
| Receptors, Interleukin-8B | 1 | 2016 | 56 | 0.030 |
Why?
|
| Atlases as Topic | 1 | 2016 | 42 | 0.030 |
Why?
|
| Vaccination | 1 | 2022 | 1123 | 0.030 |
Why?
|
| Regression Analysis | 2 | 2013 | 1546 | 0.030 |
Why?
|
| Vaginal Neoplasms | 1 | 1997 | 152 | 0.030 |
Why?
|
| Florida | 2 | 2006 | 113 | 0.030 |
Why?
|
| Poly (ADP-Ribose) Polymerase-1 | 1 | 1996 | 170 | 0.030 |
Why?
|
| Tumor Suppressor Protein p53 | 2 | 2009 | 3552 | 0.030 |
Why?
|
| Health Services Accessibility | 1 | 2022 | 761 | 0.030 |
Why?
|
| Culture Media | 1 | 1996 | 319 | 0.030 |
Why?
|
| Adipose Tissue, White | 1 | 2016 | 99 | 0.030 |
Why?
|
| Anastomotic Leak | 1 | 2016 | 71 | 0.030 |
Why?
|
| Urothelium | 1 | 2017 | 254 | 0.030 |
Why?
|
| Image-Guided Biopsy | 1 | 2018 | 327 | 0.030 |
Why?
|
| Primary Cell Culture | 1 | 2016 | 208 | 0.030 |
Why?
|
| Cryosurgery | 1 | 1997 | 167 | 0.030 |
Why?
|
| Drug Resistance | 1 | 1996 | 587 | 0.030 |
Why?
|
| Public-Private Sector Partnerships | 1 | 2014 | 26 | 0.030 |
Why?
|
| Reference Values | 2 | 2011 | 1099 | 0.030 |
Why?
|
| Bone Neoplasms | 3 | 2010 | 2576 | 0.030 |
Why?
|
| Perioperative Period | 1 | 2015 | 155 | 0.030 |
Why?
|
| Surgical Flaps | 1 | 2001 | 927 | 0.030 |
Why?
|
| Acetylation | 1 | 2016 | 508 | 0.030 |
Why?
|
| Survival Analysis | 3 | 2016 | 9180 | 0.030 |
Why?
|
| Angiogenesis Inhibitors | 1 | 2002 | 1248 | 0.030 |
Why?
|
| Research Design | 2 | 2014 | 1544 | 0.030 |
Why?
|
| Molecular Sequence Annotation | 1 | 2015 | 201 | 0.030 |
Why?
|
| Karyotyping | 1 | 1996 | 1022 | 0.030 |
Why?
|
| Diet, High-Fat | 1 | 2016 | 241 | 0.030 |
Why?
|
| Margins of Excision | 1 | 2016 | 285 | 0.030 |
Why?
|
| Superoxide Dismutase | 1 | 2015 | 266 | 0.030 |
Why?
|
| In Vitro Techniques | 1 | 2017 | 1618 | 0.030 |
Why?
|
| NF-kappa B | 1 | 2001 | 1549 | 0.030 |
Why?
|
| Adipocytes | 1 | 2016 | 305 | 0.030 |
Why?
|
| Graft Rejection | 2 | 1989 | 834 | 0.030 |
Why?
|
| Clinical Decision-Making | 1 | 2017 | 524 | 0.030 |
Why?
|
| Papillomaviridae | 1 | 2017 | 624 | 0.030 |
Why?
|
| Chromosome Aberrations | 1 | 2001 | 1960 | 0.030 |
Why?
|
| Intraoperative Complications | 1 | 2016 | 301 | 0.030 |
Why?
|
| Tumor Burden | 1 | 2019 | 1987 | 0.030 |
Why?
|
| Genetic Vectors | 3 | 2004 | 1694 | 0.030 |
Why?
|
| Waist-Hip Ratio | 1 | 2013 | 59 | 0.030 |
Why?
|
| Quantitative Trait Loci | 1 | 2015 | 374 | 0.030 |
Why?
|
| DNA-Binding Proteins | 2 | 2004 | 4821 | 0.030 |
Why?
|
| International Cooperation | 1 | 2014 | 323 | 0.030 |
Why?
|
| Nerve Tissue Proteins | 1 | 2001 | 1491 | 0.030 |
Why?
|
| Young Adult | 3 | 2020 | 21445 | 0.030 |
Why?
|
| Focus Groups | 1 | 2014 | 256 | 0.030 |
Why?
|
| Actins | 1 | 2016 | 608 | 0.030 |
Why?
|
| Image Processing, Computer-Assisted | 1 | 2000 | 1648 | 0.030 |
Why?
|
| Age of Onset | 2 | 2006 | 827 | 0.030 |
Why?
|
| In Situ Nick-End Labeling | 2 | 2004 | 448 | 0.030 |
Why?
|
| Genetic Association Studies | 1 | 2017 | 1084 | 0.030 |
Why?
|
| Gene Expression Profiling | 3 | 2011 | 5159 | 0.030 |
Why?
|
| DNA, Neoplasm | 1 | 1998 | 1910 | 0.030 |
Why?
|
| High-Throughput Nucleotide Sequencing | 1 | 2021 | 2291 | 0.030 |
Why?
|
| Cell Transformation, Neoplastic | 1 | 2001 | 2359 | 0.030 |
Why?
|
| Reoperation | 2 | 2010 | 1382 | 0.030 |
Why?
|
| Ipilimumab | 1 | 2017 | 710 | 0.030 |
Why?
|
| Epidemiologic Methods | 1 | 2012 | 254 | 0.030 |
Why?
|
| Motor Activity | 2 | 2008 | 693 | 0.030 |
Why?
|
| Administration, Oral | 1 | 2016 | 1544 | 0.030 |
Why?
|
| Multicenter Studies as Topic | 1 | 2013 | 543 | 0.030 |
Why?
|
| Sex Factors | 2 | 2008 | 2139 | 0.030 |
Why?
|
| Insurance Claim Review | 1 | 2011 | 70 | 0.030 |
Why?
|
| Adiposity | 1 | 2013 | 237 | 0.030 |
Why?
|
| Transcription, Genetic | 1 | 1999 | 3154 | 0.020 |
Why?
|
| Transcriptome | 1 | 2020 | 1859 | 0.020 |
Why?
|
| Transplantation, Heterologous | 2 | 2004 | 1082 | 0.020 |
Why?
|
| Nucleic Acid Hybridization | 2 | 2002 | 542 | 0.020 |
Why?
|
| Age Distribution | 1 | 2012 | 698 | 0.020 |
Why?
|
| Healthcare Disparities | 1 | 2016 | 598 | 0.020 |
Why?
|
| Killer Cells, Natural | 2 | 2011 | 904 | 0.020 |
Why?
|
| Cell Differentiation | 1 | 2001 | 4078 | 0.020 |
Why?
|
| Medication Adherence | 1 | 2015 | 492 | 0.020 |
Why?
|
| RNA, Long Noncoding | 1 | 2016 | 598 | 0.020 |
Why?
|
| Primary Health Care | 1 | 2016 | 787 | 0.020 |
Why?
|
| Endothelial Cells | 1 | 2016 | 1048 | 0.020 |
Why?
|
| Patient Compliance | 1 | 2014 | 667 | 0.020 |
Why?
|
| Urodynamics | 1 | 2010 | 57 | 0.020 |
Why?
|
| Reproducibility of Results | 2 | 2011 | 6009 | 0.020 |
Why?
|
| Transcription Factors | 1 | 2004 | 5270 | 0.020 |
Why?
|
| Standard of Care | 1 | 2011 | 243 | 0.020 |
Why?
|
| Emotions | 1 | 2013 | 562 | 0.020 |
Why?
|
| Muscarinic Antagonists | 1 | 2010 | 83 | 0.020 |
Why?
|
| Dissection | 1 | 2009 | 156 | 0.020 |
Why?
|
| Dose-Response Relationship, Drug | 2 | 2011 | 4938 | 0.020 |
Why?
|
| Lymphocyte Culture Test, Mixed | 1 | 1988 | 88 | 0.020 |
Why?
|
| Centrifugation, Density Gradient | 1 | 1988 | 124 | 0.020 |
Why?
|
| Microdissection | 1 | 2009 | 86 | 0.020 |
Why?
|
| Neovascularization, Physiologic | 1 | 2011 | 345 | 0.020 |
Why?
|
| Antigens, Differentiation, B-Lymphocyte | 1 | 1988 | 47 | 0.020 |
Why?
|
| Disease Models, Animal | 2 | 2017 | 7222 | 0.020 |
Why?
|
| HLA-DR Antigens | 1 | 1988 | 173 | 0.020 |
Why?
|
| Histones | 1 | 2016 | 1466 | 0.020 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 2 | 2009 | 3639 | 0.020 |
Why?
|
| Urination | 1 | 2008 | 36 | 0.020 |
Why?
|
| Physicians | 1 | 2017 | 882 | 0.020 |
Why?
|
| Agrochemicals | 1 | 2008 | 16 | 0.020 |
Why?
|
| Proteins | 1 | 1996 | 1963 | 0.020 |
Why?
|
| Cell Adhesion Molecules | 1 | 2011 | 577 | 0.020 |
Why?
|
| Surgical Procedures, Operative | 1 | 2012 | 383 | 0.020 |
Why?
|
| Histocompatibility Testing | 1 | 1989 | 447 | 0.020 |
Why?
|
| Genetic Variation | 1 | 1996 | 2086 | 0.020 |
Why?
|
| Nerve Regeneration | 1 | 2008 | 105 | 0.020 |
Why?
|
| Melanoma | 1 | 2005 | 5317 | 0.020 |
Why?
|
| Cytotoxicity Tests, Immunologic | 1 | 1987 | 84 | 0.020 |
Why?
|
| Physician-Patient Relations | 1 | 2014 | 792 | 0.020 |
Why?
|
| Protein Isoforms | 1 | 2010 | 842 | 0.020 |
Why?
|
| Suture Techniques | 1 | 2009 | 319 | 0.020 |
Why?
|
| Receptors, Antigen, B-Cell | 1 | 1988 | 171 | 0.020 |
Why?
|
| Isoantibodies | 1 | 1987 | 115 | 0.020 |
Why?
|
| Lod Score | 1 | 2007 | 157 | 0.020 |
Why?
|
| Serum Albumin | 1 | 2007 | 257 | 0.020 |
Why?
|
| Cross Reactions | 1 | 1987 | 266 | 0.020 |
Why?
|
| Physical Endurance | 1 | 2007 | 58 | 0.020 |
Why?
|
| Ki-67 Antigen | 1 | 2009 | 666 | 0.020 |
Why?
|
| Cluster Analysis | 1 | 2009 | 1053 | 0.020 |
Why?
|
| Muscle, Smooth | 1 | 2007 | 236 | 0.020 |
Why?
|
| Cell Separation | 1 | 1988 | 612 | 0.020 |
Why?
|
| Probability | 1 | 2008 | 866 | 0.020 |
Why?
|
| Digital Rectal Examination | 1 | 2006 | 14 | 0.020 |
Why?
|
| L-Lactate Dehydrogenase | 1 | 2007 | 299 | 0.020 |
Why?
|
| Spleen | 1 | 1988 | 676 | 0.020 |
Why?
|
| Matrix Metalloproteinases | 1 | 2007 | 143 | 0.020 |
Why?
|
| Haplotypes | 1 | 2008 | 856 | 0.020 |
Why?
|
| Membrane Proteins | 1 | 2017 | 2819 | 0.020 |
Why?
|
| Occupational Exposure | 1 | 2008 | 244 | 0.020 |
Why?
|
| Cell Adhesion | 1 | 1988 | 1008 | 0.020 |
Why?
|
| Practice Guidelines as Topic | 1 | 2016 | 2403 | 0.020 |
Why?
|
| Single-Blind Method | 1 | 2007 | 409 | 0.020 |
Why?
|
| Liver Neoplasms | 2 | 2007 | 4557 | 0.020 |
Why?
|
| Energy Intake | 1 | 2008 | 515 | 0.020 |
Why?
|
| Fatty Acids | 1 | 2008 | 448 | 0.020 |
Why?
|
| Platelet Endothelial Cell Adhesion Molecule-1 | 1 | 2005 | 157 | 0.020 |
Why?
|
| Chi-Square Distribution | 1 | 2008 | 1323 | 0.020 |
Why?
|
| CTLA-4 Antigen | 1 | 2009 | 657 | 0.020 |
Why?
|
| Medical Staff, Hospital | 1 | 2005 | 118 | 0.020 |
Why?
|
| HLA Antigens | 1 | 1987 | 546 | 0.020 |
Why?
|
| Graft Survival | 1 | 2008 | 1062 | 0.020 |
Why?
|
| Spiritual Therapies | 1 | 2004 | 6 | 0.020 |
Why?
|
| Databases, Factual | 1 | 2011 | 2218 | 0.020 |
Why?
|
| BCG Vaccine | 1 | 2007 | 399 | 0.020 |
Why?
|
| Carcinoma, Ductal | 1 | 2005 | 145 | 0.020 |
Why?
|
| Models, Statistical | 1 | 2010 | 1171 | 0.020 |
Why?
|
| Trinucleotide Repeats | 1 | 2004 | 106 | 0.020 |
Why?
|
| Skin | 1 | 1989 | 1259 | 0.010 |
Why?
|
| Cell Communication | 1 | 2007 | 509 | 0.010 |
Why?
|
| DNA Fragmentation | 1 | 2004 | 198 | 0.010 |
Why?
|
| Transcription Factor AP-2 | 1 | 2004 | 79 | 0.010 |
Why?
|
| Transforming Growth Factor beta1 | 1 | 2005 | 292 | 0.010 |
Why?
|
| Cross-Cultural Comparison | 1 | 2003 | 87 | 0.010 |
Why?
|
| Models, Animal | 1 | 2006 | 664 | 0.010 |
Why?
|
| Stromal Cells | 1 | 2007 | 825 | 0.010 |
Why?
|
| Polymerase Chain Reaction | 1 | 2009 | 3203 | 0.010 |
Why?
|
| Family Health | 1 | 2004 | 325 | 0.010 |
Why?
|
| Blood Platelets | 1 | 1987 | 731 | 0.010 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 1 | 2009 | 2508 | 0.010 |
Why?
|
| Lymphocytes | 1 | 1987 | 1234 | 0.010 |
Why?
|
| Cysteine Endopeptidases | 1 | 2003 | 251 | 0.010 |
Why?
|
| Interleukin-6 | 1 | 2007 | 1038 | 0.010 |
Why?
|
| Transgenes | 1 | 2004 | 557 | 0.010 |
Why?
|
| Carcinoembryonic Antigen | 1 | 2002 | 222 | 0.010 |
Why?
|
| Human Genome Project | 1 | 2001 | 64 | 0.010 |
Why?
|
| Syntaxin 1 | 1 | 2001 | 2 | 0.010 |
Why?
|
| Cloning, Molecular | 1 | 2004 | 1213 | 0.010 |
Why?
|
| Cytokines | 1 | 2011 | 2809 | 0.010 |
Why?
|
| Bortezomib | 1 | 2003 | 543 | 0.010 |
Why?
|
| NF-KappaB Inhibitor alpha | 1 | 2001 | 136 | 0.010 |
Why?
|
| Clinical Competence | 1 | 2009 | 1270 | 0.010 |
Why?
|
| Infusions, Intravenous | 1 | 2004 | 1382 | 0.010 |
Why?
|
| Tumor Necrosis Factor-alpha | 1 | 2007 | 1538 | 0.010 |
Why?
|
| Rectum | 1 | 2003 | 467 | 0.010 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p27 | 1 | 2002 | 287 | 0.010 |
Why?
|
| Blood Vessels | 1 | 2002 | 217 | 0.010 |
Why?
|
| Methods | 1 | 2000 | 189 | 0.010 |
Why?
|
| Genetic Research | 1 | 2001 | 63 | 0.010 |
Why?
|
| Quality Assurance, Health Care | 1 | 2005 | 585 | 0.010 |
Why?
|
| Cell Membrane | 1 | 2004 | 850 | 0.010 |
Why?
|
| Tyrosine | 1 | 2002 | 498 | 0.010 |
Why?
|
| Immunochemistry | 1 | 2000 | 61 | 0.010 |
Why?
|
| Keratins | 1 | 2001 | 330 | 0.010 |
Why?
|
| Chloramphenicol O-Acetyltransferase | 1 | 2000 | 118 | 0.010 |
Why?
|
| Epidermal Growth Factor | 1 | 2002 | 423 | 0.010 |
Why?
|
| Vimentin | 1 | 2001 | 253 | 0.010 |
Why?
|
| Proteasome Endopeptidase Complex | 1 | 2003 | 589 | 0.010 |
Why?
|
| Cetuximab | 1 | 2002 | 472 | 0.010 |
Why?
|
| Biomarkers | 1 | 2012 | 5047 | 0.010 |
Why?
|
| Drug Interactions | 1 | 2001 | 553 | 0.010 |
Why?
|
| Lung Neoplasms | 2 | 2007 | 11538 | 0.010 |
Why?
|
| Hospital Mortality | 1 | 2005 | 1274 | 0.010 |
Why?
|
| Epithelial Cells | 1 | 2007 | 1818 | 0.010 |
Why?
|
| Transforming Growth Factor beta | 1 | 2005 | 1130 | 0.010 |
Why?
|
| Health Surveys | 1 | 2001 | 402 | 0.010 |
Why?
|
| Adolescent | 2 | 2011 | 31252 | 0.010 |
Why?
|
| Alleles | 1 | 2005 | 2437 | 0.010 |
Why?
|
| Research | 1 | 2001 | 415 | 0.010 |
Why?
|
| DNA Primers | 1 | 2001 | 1399 | 0.010 |
Why?
|
| Receptors, Growth Factor | 1 | 1999 | 157 | 0.010 |
Why?
|
| Adenoviridae | 1 | 2004 | 1459 | 0.010 |
Why?
|
| Microcirculation | 1 | 1999 | 200 | 0.010 |
Why?
|
| Chromatin | 1 | 2004 | 942 | 0.010 |
Why?
|
| Genome, Human | 1 | 2007 | 1869 | 0.010 |
Why?
|
| Recombinant Proteins | 1 | 2004 | 2927 | 0.010 |
Why?
|
| Bleomycin | 1 | 1998 | 467 | 0.010 |
Why?
|
| Receptors, Vascular Endothelial Growth Factor | 1 | 1999 | 355 | 0.010 |
Why?
|
| Gene Expression | 1 | 2005 | 3570 | 0.010 |
Why?
|
| Cytotoxicity, Immunologic | 1 | 1999 | 675 | 0.010 |
Why?
|
| Models, Genetic | 1 | 2001 | 1113 | 0.010 |
Why?
|
| Family | 1 | 2000 | 736 | 0.010 |
Why?
|
| Heart Failure | 1 | 2010 | 2516 | 0.010 |
Why?
|
| Gene Transfer Techniques | 1 | 1999 | 716 | 0.010 |
Why?
|
| Methotrexate | 1 | 1998 | 999 | 0.010 |
Why?
|
| Receptor Protein-Tyrosine Kinases | 1 | 1999 | 661 | 0.010 |
Why?
|
| Base Sequence | 1 | 2001 | 4917 | 0.010 |
Why?
|
| Recombinant Fusion Proteins | 1 | 2000 | 1555 | 0.010 |
Why?
|
| Mice, SCID | 1 | 1999 | 1869 | 0.010 |
Why?
|
| Gene Expression Regulation | 1 | 2006 | 4053 | 0.010 |
Why?
|
| Tumor Suppressor Proteins | 1 | 2002 | 1823 | 0.010 |
Why?
|
| Mice, Knockout | 1 | 2004 | 5710 | 0.010 |
Why?
|
| Phosphorylation | 1 | 2002 | 4804 | 0.010 |
Why?
|
| Cell Cycle Proteins | 1 | 2002 | 2045 | 0.010 |
Why?
|
| Remission Induction | 1 | 1998 | 3569 | 0.010 |
Why?
|
| Child | 1 | 2012 | 29154 | 0.010 |
Why?
|
| Brain Neoplasms | 1 | 2007 | 4849 | 0.010 |
Why?
|